Quest Diagnostics Inc vs Hyatt Hotels Corporation — how do they compare? Quest Diagnostics Inc trades at $231.53 (market cap $25.48B), while Hyatt Hotels Corporation trades at $160.33 (market cap $15.02B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Hyatt Hotels Corporation for 148 Days on average.
| DGX | H | |
|---|---|---|
Market Cap | $25.48B | $15.02B |
Volume | 941,866 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $202.09 |
52-Week Low | $173.49 | $135.42 |
Typical Hold Time | 56 Days | 148 Days |
Enterprise Value | $31.23B | $18.93B |
Dividend Yield | 1.49% | 0.38% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Hyatt Hotels (H) trades at $160.27, up 1.99% with recent earnings beats but faces bearish technical signals. The stock shows mixed fundamentals with a high P/E of 196.83 and modest net income margin of 1.1%, though revenue growth to $7.10B in 2025 and strategic collaborations with Delta Air Lines highlight expansion efforts. Analyst consensus is moderately bullish with a $197.77 price target, but negative cash flow trends and elevated debt levels present challenges.
Outlook remains cautious due to valuation concerns and operational headwinds, though long-term growth initiatives offer potential upside. Key risks include profit margin volatility, high leverage, and competitive pressure. Investors should weigh analyst optimism against fundamental weaknesses before positioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →